The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis.
Stephen A KlassenJonathon W SenefeldPatrick W JohnsonRickey E CarterChad C WigginsShmuel ShohamBrenda J GrossmanJeffrey P HendersonJames M MusserEric SalazarWilliam R HartmanNicole M BouvierSean T H LiuLiise-Anne PirofskiSarah E BakerNoud van HelmondR Scott WrightDeLisa FairweatherKatelyn A BrunoNigel S PanethArturo CasadevallMichael J JoynerPublished in: medRxiv : the preprint server for health sciences (2021)
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials (RCT), 20 matched-control studies, two dose-response studies, and 96 case-reports or case series. Studies published between January 1, 2020 to January 16, 2021 were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of RCT and matched-control data demonstrated that COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.
Keyphrases
- sars cov
- case report
- cardiovascular events
- coronavirus disease
- electronic health record
- big data
- risk factors
- case control
- cardiovascular disease
- machine learning
- randomized controlled trial
- coronary artery disease
- cardiac surgery
- artificial intelligence
- respiratory syndrome coronavirus
- induced pluripotent stem cells
- health information
- data analysis